Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes

Tamami Oshige; Yui Nakamura; Yuko Sasaki; Seiko Kawano; Tsuyoshi Ohki; Munehisa Tsuruta; Ichiro Tokubuchi; Hitomi Nakayama; Kentaro Yamada; Kenji Ashida; Yuji Tajiri; Masatoshi Nomura

doi:10.2169/internalmedicine.2755-19

CASE REPORTS

Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes

Tamami Oshige, Yui Nakamura, Yuko Sasaki, Seiko Kawano, Tsuyoshi Ohki, Munehisa Tsuruta, Ichiro Tokubuchi, Hitomi Nakayama, Kentaro Yamada, Kenji Ashida, Yuji Tajiri, Masatoshi Nomura

Author information

Tamami Oshige
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan
Yui Nakamura
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan
Yuko Sasaki
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan
Seiko Kawano
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan
Tsuyoshi Ohki
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan
Munehisa Tsuruta
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan
Ichiro Tokubuchi
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan
Hitomi Nakayama
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan
Kentaro Yamada
Asakura Medical Association Hospital, Japan
Kenji Ashida
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan
Yuji Tajiri
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan
Masatoshi Nomura
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kurume University School of Medicine, Japan

Keywords: prolactinoma, type 2 diabetes mellitus, bromocriptine, insulin resistance

JOURNAL OPEN ACCESS

2019 Volume 58 Issue 21 Pages 3125-3128

DOI https://doi.org/10.2169/internalmedicine.2755-19

Browse “Advance online publication” version

Details

Abstract

A 22-year-old Japanese woman consulted an endocrinologist due to persistent galactorrhea for the past 10 months. She had hyperprolacinemia and had previously been diagnosed with type 2 diabetes mellitus based on her glycohemoglobin level of 11.6%. After two months, she was admitted to our hospital and finally diagnosed with prolactinoma. For the treatment of prolactinoma, bromocriptine 2.5 mg/day was started. After seven days, her post-prandial blood glucose levels, homeostasis model assessment of insulin resistance and plasma C-peptide levels were significantly improved. These results indicate that traditional bromocriptine can be an effective therapeutic alternative in patients with prolactinoma complicated with type 2 diabetes.

Corresponding author

Register with J-STAGE for free!